Guardant Health announced that Nasdaq has temporarily halted trading of the company’s stock. The Molecular and Clinical Genetics Panel of the FDA Medical Devices Advisory Committee will meet to review the premarket approval, or PMA, application for Shield, Guardant Health’s blood test to screen for colorectal cancer in average-risk adults.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Shield Adcom questions largely in-line, says UBS
- Guardant Health Earnings Report: Is it a Beat?
- Guardant Health raises FY24 revenue view to $675M-$685M from $655M-$670M
- Guardant Health reports Q1 EPS (46c), consensus (85c)
- Guardant Health price target lowered to $30 from $45 at Canaccord